Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex
1996

Effects of Novel Platinum Drugs on Cell Death in Ovarian Cancer Cells

publication Evidence: moderate

Author Information

Author(s): CF O'Neill, MG Ormerod, D Robertson, JC Titley, Y Cumber-Walsweer, LR Kelland

Primary Institution: Cancer Research Campaign Centre for Cancer Therapeutics, The Institute of Cancer Research

Hypothesis

The study investigates whether two novel platinum analogues induce apoptosis in human ovarian carcinoma cells.

Conclusion

The trans analogue JM335 induces apoptosis more rapidly than the cis analogue JM149, but at high concentrations, JM335 leads to non-apoptotic cell death.

Supporting Evidence

  • JM149 induced apoptosis across a range of concentrations.
  • JM335 failed to cause apoptosis at 10 x IC50.
  • JM335 showed a faster rate of apoptosis induction compared to JM149.
  • At equitoxic concentrations, levels of platinum bound to DNA were similar for both drugs.

Takeaway

This study shows that two new cancer drugs can kill ovarian cancer cells, but one works faster than the other, and too much of one can actually stop the cells from dying properly.

Methodology

The study used the SRB assay to measure cytotoxicity and flow cytometry for cell cycle analysis.

Limitations

The study does not specify the long-term effects of the drugs or their efficacy in vivo.

Participant Demographics

The study focused on the CH1 human ovarian carcinoma cell line.

Statistical Information

P-Value

0.03

Statistical Significance

p=0.03

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication